Gilead brings together HIV experts to address its vaccines and prevention

Maria Rio, Vice President and CEO of Gilead.

on the occasion of the festival of 7th edition of Milestones in basic and clinical research in HIV (hibik)Organized by Gilead, Madrid this weekend has welcomed more than 180 experts in the management of HIV, who are also involved in A. constitute scientific program with the aim of promoting debate and participation around the main advances of HIV in the past two years,

Hibik in 2022, and under the coordination of doctors Jose Alchemy, José Ramón Aribas, Santiago Moreno and Josep María Libre, the most relevant milestones and Best Jobs of 2020 and 2021 in basic translational research, epidemiology and clinical HIV. a meeting that has already become a fixed appointment of high medical science level And it has gathered more than 2,500 attendees since its creation.

“For 35 years we have been striving Changing the history of HIV And we know that significant achievements would not have been possible without the close cooperation and support of the scientific community. Meetings such as Hibik, which is celebrating its seventh edition this year, have become, once again, important events for panels of international experts and their high scientific standards. Gilead’s Pledge With research, training of health professionals and patients”, indicated Pau Arbos, director of the Gilead Spain HIV business unit.

Thus, and following the success of the previous calls, the ‘Meet the Expert’ meeting has once again been coordinated by Josep Maria Libre, a doctor at the German Trias i Pujol Hospital in Badalona, ​​who highlights that ” This session is a unique initiative that allows young national researcherEmerging figures on the international scene in the fight against the HIV pandemic, interacting with world leaders in the best clinical and basic research. In ‘Meet the Expert’, Spanish researchers have an opportunity share your projects Research and discuss them behind closed doors with invited international researchers, experts and protagonists of key projects in the field and allow them to gain visibility and even establish international collaboration”.

Furthermore, Libre states that “the continuing medical education This is essential in very dynamic fields in which relevant innovations are often incorporated. In fact, research and medical training in HIV/AIDS has been a locomotive over the past 40 years, continuing to grow. Hepatitis B and C areaDiagnostic laboratory for microbiology, epidemiology, oncology and more recently COVID among others”.

HIV Translational Basic Research

For his part, Dr. José Alchemy of the National Center for Microbiology in Madrid, has been coordinator of the Basic Translational Sciences Block, which includes Dr. Xu Yu of Harvard Medical School in the United States; Dr. Lillian Cohn of the Fred Hutchinson Cancer Center in the United States; and Vinay K Pathak, MD, Cancer Research Center, National Cancer Institute—Frederick, United States. “Basic science is very focused on the part Aspects of the Biology of Viruses, which refers to how the virus integrates into our genes. How HIV enters our cells and is closely related to the patient is because it is carried as another gene, which stays with them for life in that infected cell. For this reason, what context have I focused on putting? integration event From a biological point of view”, Alkami pointed out.

“Furthermore, the two speakers who participated in this block showed us the importance of not only the integration process, but where is the virus going to integrate, A very important approach that has changed in the last two, three years and a lot of work has been done. We’ve talked about so-called ‘elite controllers’, a small proportion of HIV patients who have managed to control the virus and does not repeat or spread, Analyzing what this means for patients and who will be candidates to support further strategies,” he said.

This expert also recalled that “it is necessary to revisit in Hibik to delve into the important aspects of HIV management. To rejuvenate the spirit of communication in Hibik, where the speaker, in addition to giving his presentations, interact with attendees, they talk in the corridors, they talk about future collaborations and science with researchers; And all this in a relaxed atmosphere. It is important to bet on this original and positive format.”

Epidemiology, prevention and public health

In connection with advances in epidemiology, coordinated by Santiago Moreno, a doctor at the Ramón y Cajal University Hospital in Madrid, “The HIV prevention Globally through three tools currently under investigation: pre-exposure prophylaxis (PrEP), the use of broad-spectrum neutralizing antibodies and the HIV vaccine. Thus, researchers have published their innovations in these three areas. Update Strategies and future prospects of ending the pandemic.”

Thus, Dr. Nyaradzo Magodi of the Clinical Trials Research Center of the University of Zimbabwe; and Larry Corey, a doctor at the Fred Hutchinson Cancer Center in the United States, “authors of papers that provide major innovations in their respective disciplines. neutralizing antibodies As a useful tool in prevention or vaccines against HIV as a pending issue. The results obtained so far have been negative, but the researchers who presented the results are among the world’s leading experts and have allowed us to discuss the current situation and the future with them. HIV VaccineMoreno added.

clinical practice

Finally, in a clinical practice session, coordinated by José Ramón Aribas, a doctor at the Hospital Universitario de la Paz in Madrid, he chose three published papers in scientific journals in 2021. Thus, John Thornhill, a doctor at Imperial College London in the United Kingdom, would echo his article published in the journal Lancet on the treatment of HIV. “An English study showing that people with HIV who had been infected for a short period of time, in addition to ART, received a medicine to shrink the reservoir Viruses and a vaccine to bring them closer to a cure. The results are not very promising in terms of reservoir reduction, but this is another example that we have to continue to investigate the possibilities of a cure”, Aribas explained.

The second study, by Priscilla Sue. Zuckerberg, a doctor at San Francisco General Hospital in the United States, has an article published in New England Medicine, in which a group HIV patient with sudden death And that, in the United States, at least, where the studies were conducted, they were related to drug overdoses.

Finally, Luca Ferretti, a doctor at the Pirbright Institute of Science in the United Kingdom, talks about an article published in Science involving a new, more virulent strain of HIV isolated in the Netherlands. “a new version which is able to destroy CD4 cells more rapidly, but the good news is that it responds to the same treatment as previous strains”, says Aribas.

While it may include statements, data or notes from health institutions or professionals, the information contained in medical writing is edited and prepared by journalists. We advise the reader to consult a health professional on any health-related questions.

Subscribe

Get the best of Newspaper delivered to your inbox daily

Most Viewed

Related Stories